title: Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
abstract: The dose-response relationship in a fixed-activity approach generally applied in the treatment of differentiated thyroid cancer was assessed using (124)I PET/CT.
  
  
  
  Pretherapeutic (124)I PET/CT images of 47 patients scheduled for radioiodine therapy were retrospectively analyzed. (124)I PET/CT images were acquired 24 and 96 h after oral administration of approximately 28 MBq of (124)I-sodium iodide. Lesions were identified as thyroid remnants or metastases (lymph node, lung, bone). After a neoteric segmentation technique allowing accurate volume estimation down to the (124)I PET spatial resolution of 0.15 mL was applied, lesions were divided into a known-volume group and a small-volume group. For the known-volume group, average lesion-absorbed dose (AD) values were calculated, whereas for the small-volume group a minimum lesion AD was estimated. Lesion response was determined on the basis of (124)I PET/CT and (131)I SPECT/CT follow-up images. A lesion not detectable on any of the follow-up images was considered a completely responding lesion. Differences in lesion AD estimations between completely and incompletely responding lesions were evaluated by Mann-Whitney U test. Moreover, receiver-operating-characteristic curves were used to test the performance of pretherapeutic (124)I PET/CT lesion AD for prediction of complete lesion response.
  
  
  
  In the approach of fixed radioiodine activity (3.0 ± 1.0 GBq), 89% of thyroid remnants and 69% of metastases responded completely. Except for the small-volume groups, the lesion AD of completely responding lesions was significantly higher than that of incompletely responding lesions. Using receiver-operating-characteristic curve analysis, it was shown that for the known-volume group, pretherapeutic (124)I PET/CT lesion dosimetry can be used as a prognostic tool to predict lesion-based (131)I therapy response with an area under the curve of 0.76 for remnants and 0.97 for metastases. The corresponding lesion AD threshold value maximizing correct complete response prediction was 90 Gy for remnants and 40 Gy for metastases.
  
  
  
  In a fixed-activity approach, a statistically significant dose-response relationship for both thyroid remnants and metastases using pretherapeutic (124)I PET/CT lesion dosimetry was found. The findings may be useful in patient management.
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands roel.wierts@mumc.nl.
authors.forename: Roel
authors.initials: R
authors.lastname: Wierts
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Boudewijn
authors.initials: B
authors.lastname: Brans
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Bas
authors.initials: B
authors.lastname: Havekes
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Gerrit J
authors.initials: GJ
authors.lastname: Kemerink
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Servais G
authors.initials: SG
authors.lastname: Halders
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Nicolaas N
authors.initials: NN
authors.lastname: Schaper
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands.
authors.forename: Walter H
authors.initials: WH
authors.lastname: Backes
authors.affiliation: Maastricht University Medical Center, Maastricht, The Netherlands University Hospital RWTH Aachen University, Aachen, Germany; and.
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
authors.affiliation: Klinik für Nuklearmedizin, Universität Duisburg-Essen, Essen, Germany.
authors.forename: Walter
authors.initials: W
authors.lastname: Jentzen
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000532:radiotherapy; D000072078:Positron Emission Tomography Computed Tomography; D012372:ROC Curve; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals
keywords: 124I; dosimetry; lesion-response relationship; radioiodine therapy; thyroid carcinoma